
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9161785/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pre-eclampsia. Lancet, The, 2010, 376, 631-644.	6.3	2,648
2	Subclassification of Preeclampsia. Hypertension in Pregnancy, 2003, 22, 143-148.	0.5	657
3	Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. The Lancet Global Health, 2021, 9, e759-e772.	2.9	645
4	The International Federation of Gynecology and Obstetrics (<scp>FIGO</scp>) initiative on preâ€eclampsia: A pragmatic guide for firstâ€trimester screening and prevention. International Journal of Gynecology and Obstetrics, 2019, 145, 1-33.	1.0	550
5	Less-Tight versus Tight Control of Hypertension in Pregnancy. New England Journal of Medicine, 2015, 372, 407-417.	13.9	516
6	Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet, The, 2000, 355, 87-92.	6.3	460
7	Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 416-438.	0.3	441
8	Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet, The, 2011, 377, 219-227.	6.3	431
9	Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2020, 324, 705.	3.8	377
10	Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ: British Medical Journal, 2003, 327, 955-0.	2.4	372
11	RETIRED: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2008, 30, S1-S2.	0.3	372
12	Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta, 2006, 27, 56-61.	0.7	355
13	Redefining Preeclampsia Using Placenta-Derived Biomarkers. Hypertension, 2013, 61, 932-942.	1.3	308
14	Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertension, 2014, 4, 105-145.	0.6	303
15	Management of hypertension in pregnancy. BMJ: British Medical Journal, 1999, 318, 1332-1336.	2.4	281
16	COVID-19 vaccination during pregnancy: coverage and safety. American Journal of Obstetrics and Gynecology, 2022, 226, 236.e1-236.e14.	0.7	265
17	SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine, 2020, 25, 100446.	3.2	250
18	Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fmsâ€like tyrosine kinase 1 and soluble endoglin in the prediction of preâ€eclampsia: a systematic review and metaâ€analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 778-787.	1.1	210

#	Article	IF	CITATIONS
19	Gestational diabetes: opportunities for improving maternal and child health. Lancet Diabetes and Endocrinology,the, 2020, 8, 793-800.	5.5	204
20	Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ: British Medical Journal, 2008, 336, 1003-1006.	2.4	195
21	DNA methylation profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsia. European Journal of Human Genetics, 2010, 18, 1006-1012.	1.4	189
22	Measuring maternal health: focus on maternal morbidity. Bulletin of the World Health Organization, 2013, 91, 794-796.	1.5	189
23	The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertension, 2022, 27, 148-169.	0.6	189
24	Widespread DNA hypomethylation at gene enhancer regions in placentas associated with early-onset pre-eclampsia. Molecular Human Reproduction, 2013, 19, 697-708.	1.3	187
25	The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study). Hypertension, 2016, 68, 1153-1159.	1.3	171
26	Chorioamnionitis with a fetal inflammatory response is associated with higher neonatal mortality, morbidity, and resource use than chorioamnionitis displaying a maternal inflammatory response only. American Journal of Obstetrics and Gynecology, 2005, 193, 708-713.	0.7	167
27	Early Administration of Low-Dose Aspirin for the Prevention of Severe and Mild Preeclampsia: A Systematic Review and Meta-Analysis. American Journal of Perinatology, 2012, 29, 551-6.	0.6	164
28	Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta, 2016, 42, 1-8.	0.7	159
29	Maternal vitamin D status in pregnancy and adverse pregnancy outcomes in a group at high risk for preâ€eclampsia. BJOC: an International Journal of Obstetrics and Gynaecology, 2010, 117, 1593-1598.	1.1	156
30	Hypertensive Disorders of Pregnancy: A Systematic Review of International Clinical Practice Guidelines. PLoS ONE, 2014, 9, e113715.	1.1	156
31	Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. American Journal of Obstetrics and Gynecology, 2005, 193, 153-163.	0.7	155
32	A Risk Prediction Model for the Assessment and Triage of Women with Hypertensive Disorders of Pregnancy in Low-Resourced Settings: The miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Multi-country Prospective Cohort Study. PLoS Medicine, 2014, 11, e1001589.	3.9	152
33	Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 624-628.	1.1	151
34	Preeclampsia. New England Journal of Medicine, 2022, 386, 1817-1832.	13.9	150
35	Decreased Placental Methylation at the H19/IGF2 Imprinting Control Region is Associated with Normotensive Intrauterine Growth Restriction but not Preeclampsia. Placenta, 2010, 31, 197-202.	0.7	148
36	Cohort Profile: The Maternalâ€Infant Research on Environmental Chemicals Research Platform. Paediatric and Perinatal Epidemiology, 2013, 27, 415-425.	0.8	146

#	Article	IF	CITATIONS
37	Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. The Lancet Child and Adolescent Health, 2018, 2, 93-102.	2.7	146
38	An international trial of antioxidants in the prevention of preeclampsia (INTAPP). American Journal of Obstetrics and Gynecology, 2010, 202, 239.e1-239.e10.	0.7	129
39	In Response. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 575-576.	0.3	129
40	The 24-hour urine collection: gold standard or historical practice?. American Journal of Obstetrics and Gynecology, 2008, 199, 625.e1-625.e6.	0.7	126
41	Maternity services in the UK during the coronavirus disease 2019 pandemic: a national survey of modifications to standard care. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 880-889.	1.1	125
42	Could an infectious trigger explain the differential maternal response to the shared placental pathology of preeclampsia and normotensive intrauterine growth restriction?. Acta Obstetricia Et Gynecologica Scandinavica, 2002, 81, 642-648.	1.3	120
43	How to manage hypertension in pregnancy effectively. British Journal of Clinical Pharmacology, 2011, 72, 394-401.	1.1	120
44	Fall in Mean Arterial Pressure and Fetal Growth Restriction in Pregnancy Hypertension: An Updated Metaregression Analysis. Journal of Obstetrics and Gynaecology Canada, 2002, 24, 941-945.	0.3	111
45	Maternal neutrophil apoptosis in normal pregnancy, preeclampsia, and normotensive intrauterine growth restriction. American Journal of Obstetrics and Gynecology, 1999, 181, 408-414.	0.7	103
46	Improving the quality of care for infants: a cluster randomized controlled trial. Cmaj, 2009, 181, 469-476.	0.9	103
47	Preventing deaths due to the hypertensive disorders of pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 36, 83-102.	1.4	102
48	RETIRED: Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 516-529.	0.3	100
49	STRIDER: Sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction – a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Systematic Reviews, 2014, 3, 23.	2.5	100
50	Does Cesarean Section Reduce Postpartum Urinary Incontinence? A Systematic Review. Birth, 2007, 34, 228-237.	1.1	98
51	Early Onset Pre-Eclampsia Is Associated with Altered DNA Methylation of Cortisol-Signalling and Steroidogenic Genes in the Placenta. PLoS ONE, 2013, 8, e62969.	1.1	98
52	Pre-eclampsia in low and middle income countries. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 537-548.	1.4	97
53	Seasonal variation in geographical access to maternal health services in regions of southern Mozambique. International Journal of Health Geographics, 2017, 16, 1.	1.2	97
54	Constructing maternal morbidity – towards a standard tool to measure and monitor maternal health beyond mortality. BMC Pregnancy and Childbirth, 2016, 16, 45.	0.9	95

#	Article	IF	CITATIONS
55	Global changes in maternity care provision during the COVID-19 pandemic: A systematic review and meta-analysis. EClinicalMedicine, 2021, 37, 100947.	3.2	92
56	Canadian Pediatric Surgical Network: a population-based pediatric surgery network and database for analyzing surgical birth defects. The first 100 cases of gastroschisis. Journal of Pediatric Surgery, 2008, 43, 30-34.	0.8	91
57	Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?. American Journal of Obstetrics and Gynecology, 2012, 206, 163.e1-163.e7.	0.7	91
58	Pre-eclampsia: An Update. Current Hypertension Reports, 2014, 16, 454.	1.5	90
59	Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 330-339.	6.3	90
60	Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet, The, 2019, 394, 1011-1021.	6.3	89
61	Expectant Management of Severe Preeclampsia Remote from Term: A Structured Systematic Review. Hypertension in Pregnancy, 2009, 28, 312-347.	0.5	88
62	Current CHS and NHBPEP Criteria for Severe Preeclampsia Do Not Uniformly Predict Adverse Maternal or Perinatal Outcomes. Hypertension in Pregnancy, 2007, 26, 447-462.	0.5	87
63	Preeclampsia and future cardiovascular risk. Expert Review of Cardiovascular Therapy, 2007, 5, 283-294.	0.6	86
64	Lowâ€dose calcium supplementation for preventing preâ€eclampsia: a systematic review and commentary. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 951-957.	1.1	84
65	Barriers and facilitators to health care seeking behaviours in pregnancy in rural communities of southern Mozambique. Reproductive Health, 2016, 13, 31.	1.2	81
66	Instituting Surveillance Guidelines and Adverse Outcomes in Preeclampsia. Obstetrics and Gynecology, 2007, 110, 121-127.	1.2	80
67	Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOC: an International Journal of Obstetrics and Gynaecology, 2014, 121, 1210-1218.	1.1	80
68	Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertension, 2018, 11, 115-123.	0.6	79
69	The Control of Hypertension In Pregnancy Study pilot trial. BJOG: an International Journal of Obstetrics and Gynaecology, 2007, 114, 770-e20.	1.1	75
70	Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. American Journal of Obstetrics and Gynecology, 2011, 205, 469.e1-469.e8.	0.7	73
71	The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis. PLoS Medicine, 2019, 16, e1002783.	3.9	72
72	Development of mHealth Applications for Pre-Eclampsia Triage. IEEE Journal of Biomedical and Health Informatics, 2014, 18, 1857-1864.	3.9	71

#	Article	IF	CITATIONS
73	Human Placental-Specific Epipolymorphism and its Association with Adverse Pregnancy Outcomes. PLoS ONE, 2009, 4, e7389.	1.1	71
74	Prediction of preâ€eclampsia: review of reviews. Ultrasound in Obstetrics and Gynecology, 2019, 54, 16-27.	0.9	69
75	Guidelines—similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension. American Journal of Obstetrics and Gynecology, 2022, 226, S1222-S1236.	0.7	69
76	A core outcome set for preâ€eclampsia research: an international consensus development study. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 1516-1526.	1.1	68
77	Tollâ€like receptors 2 and 4 and the cryopyrin inflammasome in normal pregnancy and preâ€eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 2010, 117, 99-108.	1.1	67
78	Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1143-1151.	1.1	63
79	Usability and Feasibility of PIERS on the Move: An mHealth App for Pre-Eclampsia Triage. JMIR MHealth and UHealth, 2015, 3, e37.	1.8	61
80	Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. Journal of Obstetrics and Gynaecology Canada, 2022, 44, 547-571.e1.	0.3	60
81	Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: A therapeutic opportunity?*. Critical Care Medicine, 2002, 30, 1883-1892.	0.4	59
82	Prevention and treatment of postpartum hypertension. The Cochrane Library, 2013, , CD004351.	1.5	59
83	Is the closest health facility the one used in pregnancy care-seeking? A cross-sectional comparative analysis of self-reported and modelled geographical access to maternal care in Mozambique, India and Pakistan. International Journal of Health Geographics, 2020, 19, 1.	1.2	59
84	Hypomethylation of the LEP gene in placenta and elevated maternal leptin concentration in early onset pre-eclampsia. Molecular and Cellular Endocrinology, 2013, 367, 64-73.	1.6	58
85	The gastroschisis prognostic score: reliable outcome prediction in gastroschisis. Journal of Pediatric Surgery, 2012, 47, 1111-1117.	0.8	57
86	Prediction of Pediatric Outcome after Prenatal Diagnosis and Expectant Antenatal Management of Congenital Cystic Adenomatoid Malformation. Fetal Diagnosis and Therapy, 2012, 31, 94-102.	0.6	56
87	Maternal peripheral blood leukocytes in normal and pre-eclamptic pregnancies. BJOG: an International Journal of Obstetrics and Gynaecology, 1999, 106, 576-581.	1.1	55
88	Do Commonly Used Oral Antihypertensives Alter Fetal or Neonatal Heart Rate Characteristics? A Systematic Review. Hypertension in Pregnancy, 2004, 23, 155-169.	0.5	55
89	The Prediction of Adverse Maternal Outcomes in Preeclampsia. Journal of Obstetrics and Gynaecology Canada, 2004, 26, 871-879.	0.3	55
90	Acute Pulmonary Oedema as a Complication of Hypertension During Pregnancy. Hypertension in Pregnancy, 2011, 30, 169-179.	0.5	54

#	Article	IF	CITATIONS
91	Serious Perinatal Complications of Non-Proteinuric Hypertension: An International, Multicentre, Retrospective Cohort Study. Journal of Obstetrics and Gynaecology Canada, 2003, 25, 372-382.	0.3	53
92	Predicting Adverse Outcomes in Women with Severe Pre-eclampsia. Seminars in Perinatology, 2009, 33, 152-157.	1.1	53
93	Abnormal Liver Function Tests as Predictors of Adverse Maternal Outcomes in Women With Preeclampsia. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 995-1004.	0.3	53
94	The hypertensive disorders of pregnancy (29.3). Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 643-657.	1.4	51
95	Utilization of maternal health care services and their determinants in Karnataka State, India. Reproductive Health, 2016, 13, 37.	1.2	51
96	Assessing the role of placental trisomy in preeclampsia and intrauterine growth restriction. Prenatal Diagnosis, 2010, 30, 1-8.	1.1	50
97	Maternal vitamin D3 supplementation at 50 μg/d protects against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized controlled trial of 3 doses of vitamin D beginning in gestation and continued in lactation. American Journal of Clinical Nutrition, 2015, 102, 402-410.	2.2	50
98	Women's experiences of maternity service reconfiguration during the COVID-19 pandemic: A qualitative investigation. Midwifery, 2021, 102, 103116.	1.0	50
99	PIERS Proteinuria: Relationship With Adverse Maternal and Perinatal Outcome. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 588-597.	0.3	49
100	Optimal timing of delivery in pregnancies with pre-existing hypertension. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 49-54.	1.1	49
101	A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertension, 2012, 2, 8-15.	0.6	48
102	A scoping review of geographic information systems in maternal health. International Journal of Gynecology and Obstetrics, 2016, 134, 13-17.	1.0	48
103	A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertension, 2016, 6, 274-278.	0.6	48
104	An association between cytomegalovirus infection and preâ€eclampsia: a case–control study and data synthesis. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 1162-1167.	1.3	43
105	STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. BMC Pregnancy and Childbirth, 2017, 17, 440.	0.9	43
106	No. 376-Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada, 2019, 41, 505-522.	0.3	43
107	The Active Implementation of Pregnancy Hypertension Guidelines in British Columbia. Obstetrics and Gynecology, 2010, 116, 659-666.	1.2	42
108	Uric Acid as a Predictor of Adverse Maternal and Perinatal Outcomes in Women Hospitalized With Preeclampsia. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 870-877.	0.3	42

#	Article	IF	CITATIONS
109	Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia. Hypertension, 2018, 71, 659-665.	1.3	41
110	Tackling poorly selected, collected, andÂreported outcomes in obstetrics andÂgynecology research. American Journal of Obstetrics and Gynecology, 2019, 220, 71.e1-71.e4.	0.7	41
111	Change in obstetric attendance and activities during the COVID-19 pandemic. Lancet Infectious Diseases, The, 2021, 21, e115.	4.6	41
112	Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. BMC Medicine, 2017, 15, 68.	2.3	40
113	State-of-the-Art Diagnosis and Treatment of Hypertension in Pregnancy. Mayo Clinic Proceedings, 2018, 93, 1664-1677.	1.4	40
114	Gastroschisis closure—does method really matter?. Journal of Pediatric Surgery, 2008, 43, 874-878.	0.8	39
115	Assessment, surveillance and prognosis in pre-eclampsia. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 449-462.	1.4	39
116	Less-Tight versus Tight Control of Hypertension in Pregnancy. New England Journal of Medicine, 2015, 372, 2366-2368.	13.9	39
117	Multiple Organ Dysfunction Score Is Superior to the Obstetric-Specific Sepsis in Obstetrics Score in Predicting Mortality in Septic Obstetric Patients. Critical Care Medicine, 2017, 45, e49-e57.	0.4	39
118	Levels of antibodies against cytomegalovirus and Chlamydophila pneumoniae are increased in early onset pre-eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 725-730.	1.1	38
119	Women's Views of Their Experiences in the CHIPS (Control of Hypertension in Pregnancy Study) Pilot Trial. Hypertension in Pregnancy, 2007, 26, 371-387.	0.5	38
120	Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. American Journal of Obstetrics and Gynecology, 2021, 224, 518.e1-518.e11.	0.7	38
121	Decidual NK cell-derived conditioned medium enhances capillary tube and network organization in an extravillous cytotrophoblast cell lineâ~†. Placenta, 2010, 31, 213-221.	0.7	36
122	Determinants of health care seeking behaviour during pregnancy in Ogun State, Nigeria. Reproductive Health, 2016, 13, 32.	1.2	36
123	The Role of Decidual Natural Killer Cells in Normal Placentation and in the Pathogenesis of Preeclampsia. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 467-476.	0.3	35
124	Performance of Estimated Glomerular Filtration Rate Prediction Equations in Preeclamptic Patients. American Journal of Perinatology, 2011, 28, 425-430.	0.6	35
125	Performance of the fullPIERS model in predicting adverse maternal outcomes in preâ€eclampsia using patient data from the PIERS (Preâ€eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 113-118.	1.1	35
126	Control of hypertension in pregnancy. Current Hypertension Reports, 2009, 11, 429-436.	1.5	34

#	Article	IF	CITATIONS
127	Validating the Performance of the Modified Early Obstetric Warning System Multivariable Model to Predict Maternal Intensive Care Unit Admission. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 728-733.e3.	0.3	34
128	A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of preâ€eclampsia. International Journal of Gynecology and Obstetrics, 2021, 154, 3-31.	1.0	34
129	The association between preeclampsia and placental trisomy 16 mosaicism. Prenatal Diagnosis, 2006, 26, 956-961.	1.1	33
130	Pre-eclampsia and increased cardiovascular risk. BMJ: British Medical Journal, 2007, 335, 945-946.	2.4	32
131	Preeclampsia in Low and Middle Income Countries—Health Services Lessons Learned From the PRE-EMPT (PRE-Eclampsia–Eclampsia Monitoring, Prevention & Treatment) Project. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 917-926.	0.3	32
132	Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the smallâ€forâ€gestationalâ€age infant in women presenting with reduced symphysis–fundus height. Ultrasound in Obstetrics and Gynecology, 2015, 46, 182-190.	0.9	32
133	Mothers' satisfaction with care during facility-based childbirth: a cross-sectional survey in southern Mozambique. BMC Pregnancy and Childbirth, 2019, 19, 303.	0.9	32
134	Title is missing!. Sepsis, 2000, 4, 43-47.	0.5	31
135	Evidence-based management for preeclampsia. Frontiers in Bioscience - Landmark, 2007, 12, 2876.	3.0	31
136	IFN-Â-mediated extravillous trophoblast outgrowth inhibition in first trimester explant culture: a role for insulin-like growth factors. Molecular Human Reproduction, 2008, 14, 281-289.	1.3	31
137	Caesarean Section on Maternal Request: Risks and Benefits in Healthy Nulliparous Women and Their Infants. Journal of Obstetrics and Gynaecology Canada, 2009, 31, 808-817.	0.3	31
138	Toll-like Receptor-3 Stimulation Upregulates sFLT-1 Production by Trophoblast Cells. Placenta, 2009, 30, 774-779.	0.7	30
139	The Management of Severe Hypertension. Seminars in Perinatology, 2009, 33, 138-142.	1.1	30
140	<scp>CMV</scp> Infection, <scp>TLR</scp> â€2 and â€4 Expression, and Cytokine Profiles in Earlyâ€Onset Preeclampsia with <scp>HELLP</scp> Syndrome. American Journal of Reproductive Immunology, 2014, 71, 379-386.	1.2	30
141	Development and validation of Prediction models for Risks of complications in Early-onset Pre-eclampsia (PREP): a prospective cohort study. Health Technology Assessment, 2017, 21, 1-100.	1.3	30
142	Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy. Hypertension, 2017, 70, 1228-1237.	1.3	29
143	Toll-like Receptor Gene Polymorphisms and Preeclampsia Risk: A Case-Control Study and Data Synthesis. Hypertension in Pregnancy, 2010, 29, 390-398.	O.5	28
144	MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada. Implementation Science, 2018, 13, 8.	2.5	28

#	Article	IF	CITATIONS
145	Validation of the WHO Disability Assessment Schedule (WHODAS 2.0) 12-item tool against the 36-item version for measuring functioning and disability associated with pregnancy and history of severe maternal morbidity. International Journal of Gynecology and Obstetrics, 2018, 141, 39-47.	1.0	28
146	The Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised trials in Mozambique, Pakistan, and India: an individual participant-level meta-analysis. Lancet, The, 2020, 396, 553-563.	6.3	28
147	Community level interventions for pre-eclampsia (CLIP) in India: A cluster randomised controlled trial. Pregnancy Hypertension, 2020, 21, 166-175.	0.6	28
148	Antihypertensive Medications in Management of Gestational Hypertension-Preeclampsia. Clinical Obstetrics and Gynecology, 2005, 48, 441-459.	0.6	27
149	REVIEW ARTICLE: Tollâ€Like Receptor Signaling and Preâ€Eclampsia. American Journal of Reproductive Immunology, 2010, 63, 7-16.	1.2	27
150	Ethics review as a component of institutional approval for a multicentre continuous quality improvement project: the investigator's perspective. BMC Health Services Research, 2010, 10, 223.	0.9	27
151	Oxygen Saturation as a Predictor of Adverse Maternal Outcomes in Women with Preeclampsia. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 705-714.	0.3	27
152	Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Services Research, 2013, 13, 527.	0.9	27
153	Magnesium Sulphate for the Management of Preeclampsia and Eclampsia in Low and Middle Income Countries: A Systematic Review of Tested Dosing Regimens. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 154-163.	0.3	27
154	Assessing the Incremental Value of Blood Oxygen Saturation (SpO2) in the miniPIERS (Pre-eclampsia) Tj ETQqO 2015, 37, 16-24.	0 0 rgBT /0 0.3	Overlock 10 Tf 27
155	The Usefulness of the APACHE II Score in Obstetric Critical Care: A Structured Review. Journal of Obstetrics and Gynaecology Canada, 2016, 38, 909-918.	0.3	27
156	The CRADLE vital signs alert: qualitative evaluation of a novel device designed for use in pregnancy by healthcare workers in low-resource settings. Reproductive Health, 2018, 15, 5.	1.2	27
157	Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia. Pregnancy Hypertension, 2019, 15, 42-50.	0.6	27
158	Using Clinical Symptoms to Predict Adverse Maternal and Perinatal Outcomes in Women With Preeclampsia: Data From the PIERS (Pre-eclampsia Integrated Estimate of RiSk) Study. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 803-809.	0.3	26
159	A prediction model for short-term neonatal outcomes in severe early-onset fetal growth restriction. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 241, 109-118.	0.5	26
160	Community-level interventions for pre-eclampsia (CLIP) in Pakistan: A cluster randomised controlled trial. Pregnancy Hypertension, 2020, 22, 109-118.	0.6	26
161	Prediction of stillbirth: an umbrella review of evaluation of prognostic variables. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 238-250.	1.1	26
162	The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: An exploratory, randomized placebo controlled study. Pregnancy Hypertension, 2015, 5, 273-279.	0.6	25

#	Article	IF	CITATIONS
163	The feasibility of community level interventions for pre-eclampsia in South Asia and Sub-Saharan Africa: a mixed-methods design. Reproductive Health, 2016, 13, 56.	1.2	25
164	Community perspectives on the determinants of maternal health in rural southern Mozambique: a qualitative study. Reproductive Health, 2016, 13, 112.	1.2	25
165	External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries. Hypertension, 2017, 69, 705-711.	1.3	25
166	Influence of Gestational Age at Initiation of Antihypertensive Therapy. Hypertension, 2018, 71, 1170-1177.	1.3	25
167	Calcium for preâ€eclampsia prevention: A systematic review and network metaâ€analysis to guide personalised antenatal care. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1833-1843.	1.1	25
168	Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 179, 58-62.	0.5	24
169	Community health worker knowledge and management of pre-eclampsia in rural Karnataka State, India. Reproductive Health, 2016, 13, 113.	1.2	24
170	What matters in preeclampsia are the associated adverse outcomes: the view from Canada. Current Opinion in Obstetrics and Gynecology, 2008, 20, 110-115.	0.9	23
171	The Role of Platelet Counts in the Assessment of Inpatient Women With Preeclampsia. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 900-908.	0.3	23
172	Community perceptions of pre-eclampsia and eclampsia in Ogun State, Nigeria: a qualitative study. Reproductive Health, 2016, 13, 57.	1.2	23
173	Community-level interventions for pre-eclampsia (CLIP) in Mozambique: A cluster randomised controlled trial. Pregnancy Hypertension, 2020, 21, 96-105.	0.6	23
174	An internally validated prediction model for critical COVID-19 infection and intensive care unit admission in symptomatic pregnant women. American Journal of Obstetrics and Gynecology, 2022, 226, 403.e1-403.e13.	0.7	23
175	A Survey of Canadian Practitioners Regarding the Management of the Hypertensive Disorders of Pregnancy. Hypertension in Pregnancy, 2004, 23, 61-74.	0.5	22
176	Community's perceptions of pre-eclampsia and eclampsia in Sindh Pakistan: a qualitative study. Reproductive Health, 2016, 13, 36.	1.2	22
177	Community health worker knowledge and management of pre-eclampsia in southern Mozambique. Reproductive Health, 2016, 13, 105.	1.2	22
178	Flow cytometric assessment of feto-maternal hemorrhage; a comparison with Betke–Kleihauer. Prenatal Diagnosis, 2007, 27, 641-643.	1.1	21
179	<i>Chlamydia pneumoniae</i> Infection in Preeclampsia. Hypertension in Pregnancy, 2010, 29, 468-477.	0.5	21
180	Maternal and Perinatal Outcomes of Pregnancies Delivered at 23 Weeks' Gestation. Journal of Obstetrics and Gynaecology Canada, 2015, 37, 214-224.	0.3	21

#	Article	IF	CITATIONS
181	Health care provider knowledge and routine management of pre-eclampsia in Pakistan. Reproductive Health, 2016, 13, 104.	1.2	21
182	The Placental Distal Villous Hypoplasia Pattern: Interobserver Agreement and Automated Fractal Dimension as an Objective Metric. Pediatric and Developmental Pathology, 2016, 19, 31-36.	0.5	21
183	Effects of Maternal Nutritional Supplements and Dietary Interventions on Placental Complications: An Umbrella Review, Meta-Analysis and Evidence Map. Nutrients, 2021, 13, 472.	1.7	21
184	Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses. Hypertension, 2022, 79, 614-628.	1.3	21
185	Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension, 2015, 5, 315-321.	0.6	20
186	Community perceptions of pre-eclampsia and eclampsia in southern Mozambique. Reproductive Health, 2016, 13, 33.	1.2	20
187	Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique. Hypertension, 2017, 69, 469-474.	1.3	20
188	A Survey of Canadian Practitioners Regarding Diagnosis and Evaluation of the Hypertensive Disorders of Pregnancy. Hypertension in Pregnancy, 2004, 23, 197-209.	0.5	19
189	Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction. The Lancet Child and Adolescent Health, 2019, 3, e2-e3.	2.7	19
190	Health and socio-demographic profile of women of reproductive age in rural communities of southern Mozambique. PLoS ONE, 2018, 13, e0184249.	1.1	19
191	Effect of Magnesium Sulphate on Fetal Heart Rate Parameters: A Systematic Review. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 1055-1064.	0.3	18
192	Labetalol for hypertension in pregnancy. Expert Opinion on Drug Safety, 2015, 14, 453-461.	1.0	18
193	Community perceptions of pre-eclampsia in rural Karnataka State, India: a qualitative study. Reproductive Health, 2016, 13, 35.	1.2	18
194	Prevention and treatment of postpartum hypertension. , 2005, , CD004351.		17
195	Placental Pathology and Clinical Outcomes in a Cohort of Infants Admitted to a Neonatal Intensive Care Unit. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 315-323.	0.3	17
196	Pharmacotherapy for Preeclampsia in Low and Middle Income Countries: An Analysis of Essential Medicines Lists. Journal of Obstetrics and Gynaecology Canada, 2013, 35, 215-223.	0.3	17
197	Placental DNA methylation at term reflects maternal serum levels of INHA and FN1, but not PAPPA, early in pregnancy. BMC Medical Genetics, 2015, 16, 111.	2.1	17
198	Control of Hypertension In Pregnancy Study randomised controlled trial—are the results dependent on the choice of labetalol or methyldopa?. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1135-1141.	1.1	17

#	Article	IF	CITATIONS
199	Extending the scope of pooled analyses of individual patient biomarker data from heterogeneous laboratory platforms and cohorts using merging algorithms. Pregnancy Hypertension, 2016, 6, 53-59.	0.6	17
200	A process evaluation plan for assessing a complex community-based maternal health intervention in Ogun State, Nigeria. BMC Health Services Research, 2017, 17, 238.	0.9	17
201	Management of non-severe pregnancy hypertension – A summary of the CHIPS Trial (Control of) Tj ETQq1 1 0.	784314 rg 0.6	BT/Overlock
202	Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis. Health Technology Assessment, 2020, 24, 1-252.	1.3	17
203	Toward point-of-care ultrasound estimation of fetal gestational age from the trans-cerebellar diameter using CNN-based ultrasound image analysis. Journal of Medical Imaging, 2020, 7, 1.	0.8	17
204	The complications of hypertension in pregnancy. Minerva Medica, 2005, 96, 287-302.	0.3	17
205	Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implementation Science, 2015, 10, 76.	2.5	16
206	Potential for task-sharing to Lady Health Workers for identification and emergency management of pre-eclampsia at community level in Pakistan. Reproductive Health, 2016, 13, 107.	1.2	16
207	Community health workers' knowledge and practice in relation to pre-eclampsia in Ogun State, Nigeria: an essential bridge to maternal survival. Reproductive Health, 2016, 13, 108.	1.2	16
208	Benchmarking the Hypertensive Disorders of Pregnancy. Pregnancy Hypertension, 2016, 6, 279-284.	0.6	16
209	Toward personalized management of chronic hypertension in pregnancy. American Journal of Obstetrics and Gynecology, 2022, 226, S1196-S1210.	0.7	16
210	Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS ONE, 2017, 12, e0166623.	1.1	16
211	Erythropoiesis and renal transplant pregnancy. Clinical Transplantation, 2000, 14, 127-135.	0.8	15
212	Placental Weight in Pregnancies With Trisomy Confined to the Placenta. Journal of Obstetrics and Gynaecology Canada, 2009, 31, 605-610.	0.3	15
213	Development and internal validation of the multivariable CIPHER (Collaborative Integrated Pregnancy) Tj ETQq1 🛾	1 0,784314 2.5	1 rgBT /Overl
214	The impact of hypertension, hemorrhage, and other maternal morbidities on functioning in the postpartum period as assessed by the WHODAS 2.0 36-item tool. International Journal of Gynecology and Obstetrics, 2018, 141, 55-60.	1.0	15
215	NPFF increases fusogenic proteins syncytin 1 and syncytin 2 via GCM1 in first trimester primary human cytotrophoblast cells. FASEB Journal, 2020, 34, 9419-9432.	0.2	15
216	Can risk prediction models help us individualise stillbirth prevention? A systematic review and critical appraisal of published risk models. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 214-224.	1.1	15

#	Article	IF	CITATIONS
217	A randomised controlled trial of biopsy forceps and cannula aspiration for transcervical chorionic villus sampling. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 559-566.	1.1	14
218	What is the Role of Out-of-Office BP Measurement in Hypertensive Pregnancy?. Hypertension in Pregnancy, 2008, 27, 95-101.	0.5	14
219	Monitoring Renal Function in Hypertensive Pregnancy. Hypertension in Pregnancy, 2010, 29, 318-329.	0.5	14
220	Postpartum Hyperkalemia Associated with Magnesium Sulfate. Hypertension in Pregnancy, 2011, 30, 481-484.	0.5	14
221	Improving maternal and perinatal outcomes in the hypertensive disorders of pregnancy: A vision of a communityâ€focused approach. International Journal of Gynecology and Obstetrics, 2012, 119, S30-4.	1.0	14
222	PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and Treatment): A low and middle income country initiative to reduce the global burden of maternal, fetal and infant death and disease related to pre-eclampsia. Pregnancy Hypertension, 2013, 3, 199-202.	0.6	14
223	Human resource constraints and the prospect of task-sharing among community health workers for the detection of early signs of pre-eclampsia inÂOgun State, Nigeria. Reproductive Health, 2016, 13, 111.	1.2	14
224	External validation, update and development of prediction models for pre-eclampsia using an Individual Participant Data (IPD) meta-analysis: the International Prediction of Pregnancy Complication Network (IPPIC pre-eclampsia) protocol. Diagnostic and Prognostic Research, 2017, 1, 16.	0.8	14
225	Causes and circumstances of maternal death: a secondary analysis of the Community-Level Interventions for Pre-eclampsia (CLIP) trials cohort. The Lancet Global Health, 2021, 9, e1242-e1251.	2.9	14
226	<scp>M</scp> aternal floor infarction: <scp>M</scp> anagement of an underrecognized pathology. Journal of Obstetrics and Gynaecology Research, 2014, 40, 293-296.	0.6	13
227	Risk factors for postpartum sepsis: a nested case-control study. BMC Pregnancy and Childbirth, 2020, 20, 297.	0.9	13
228	Pregnancy hypertension diagnosis and care in COVIDâ€19 era and beyond. Ultrasound in Obstetrics and Gynecology, 2020, 56, 7-10.	0.9	13
229	Genomic imbalances in the placenta are associated with poor fetal growth. Molecular Medicine, 2021, 27, 3.	1.9	13
230	Implementation of a Community Transport Strategy to Reduce Delays in Seeking Obstetric Care in Rural Mozambique. Global Health, Science and Practice, 2021, 9, S122-S136.	0.6	13
231	Maternal Dietary Patterns and Pregnancy Hypertension in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. Advances in Nutrition, 2021, 12, 2387-2400.	2.9	13
232	An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertension, 2013, 3, 166-171.	0.6	12
233	Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique. Pregnancy Hypertension, 2018, 11, 26-31.	0.6	12
234	Characterization of maternal plasma biomarkers associated with delivery of small and large for gestational age infants in the MIREC study cohort. PLoS ONE, 2018, 13, e0204863.	1.1	12

#	Article	IF	CITATIONS
235	The feasibility of task-sharing the identification, emergency treatment, and referral for women with pre-eclampsia by community health workers in India. Reproductive Health, 2018, 15, 101.	1.2	12
236	Placental growth factor as an indicator of fetal growth restriction in lateâ€onset smallâ€forâ€gestational age pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 89-95.	0.4	12
237	External validation of prognostic models predicting pre-eclampsia: individual participant data meta-analysis. BMC Medicine, 2020, 18, 302.	2.3	12
238	The PRECISE (PREgnancy Care Integrating translational Science, Everywhere) Network's first protocol: deep phenotyping in three sub-Saharan African countries. Reproductive Health, 2020, 17, 51.	1.2	12
239	COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm. Lancet Infectious Diseases, The, 2021, 21, 1627.	4.6	12
240	Instruments for chorionic villus sampling for prenatal diagnosis. The Cochrane Library, 2013, , CD000114.	1.5	11
241	Genome-wide DNA methylation identifies trophoblast invasion-related genes: Claudin-4 and Fucosyltransferase IV control mobility via altering matrix metalloproteinase activity. Molecular Human Reproduction, 2015, 21, 452-465.	1.3	11
242	Visual or automated dipstick testing for proteinuria in pregnancy?. Pregnancy Hypertension, 2017, 7, 50-53.	0.6	11
243	Reference ranges of the WHO Disability Assessment Schedule (WHODAS 2.0) score and diagnostic validity of its 12-item version in identifying altered functioning in healthy postpartum women. International Journal of Gynecology and Obstetrics, 2018, 141, 48-54.	1.0	11
244	Predisposition to superimposed preeclampsia in women with chronic hypertension: endothelial, renal, cardiac, and placental factors in a prospective longitudinal cohort. Hypertension in Pregnancy, 2020, 39, 326-335.	0.5	11
245	Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data. Pregnancy Hypertension, 2020, 19, 87-93.	0.6	11
246	The Association Between Early Membrane Rupture, Latency, Clinical Chorioamnionitis, Neonatal Infection, and Adverse Perinatal Outcomes in Twin Pregnancies Complicated by Preterm Prelabour Rupture of Membranes. Twin Research and Human Genetics, 2003, 6, 257-262.	1.5	11
247	Variations in Early and Intermediate Neonatal Outcomes for Inborn Infants Admitted to a Canadian NICU and Born of Hypertensive Pregnancies. Journal of Obstetrics and Gynaecology Canada, 2005, 27, 25-32.	0.3	10
248	A Surgical Virtual Reality Simulator Distinguishes Between Expert Gynecologic Laparoscopic Surgeons and Perinatologists. Journal of the Society of Laparoendoscopic Surgeons, 2011, 15, 365-372.	0.5	10
249	The Canadian Perinatal Network: A National Network Focused on Threatened Preterm Birth at 22 to 28 Weeks' Gestation. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 111-120.	0.3	10
250	Decidual NK Cellâ€Ðerived Conditioned Medium (dNK M) Mediates VEGF Secretion in Extravillous Cytotrophoblasts. American Journal of Reproductive Immunology, 2012, 67, 101-111.	1.2	10
251	Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PREâ€EMPT. International Journal of Gynecology and Obstetrics, 2015, 131, S10-5.	1.0	10
252	The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). Hypertension, 2016, 68, 1049-1055.	1.3	10

PETER VON DADELSZEN

#	Article	IF	CITATIONS
253	Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 763-776.	1.3	10
254	Timing of delivery in a high-risk obstetric population: a clinical prediction model. BMC Pregnancy and Childbirth, 2017, 17, 202.	0.9	10
255	COVID-19 and maternal and perinatal outcomes – Authors' reply. The Lancet Global Health, 2021, 9, e1066.	2.9	10
256	Blood pressure thresholds in pregnancy for identifying maternal and infant risk: a secondary analysis of Community-Level Interventions for Pre-eclampsia (CLIP) trial data. The Lancet Global Health, 2021, 9, e1119-e1128.	2.9	10
257	SARS-CoV-2 vaccination in pregnancy: a unique opportunity for equity. Lancet, The, 2021, 398, 951.	6.3	10
258	Urinary Dipstick Proteinuria Testing: Does Automated Strip Analysis Offer an Advantage Over Visual Testing?. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 605-612.	0.3	9
259	Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. Journal of Obstetrics and Gynaecology Canada, 2015, 37, 975-987.	0.3	9
260	Guidelines for creating framework data for GIS analysis in low―and middleâ€income countries. Canadian Geographer / Geographie Canadien, 2016, 60, 320-332.	1.0	9
261	The Impact of a History of Adverse Childhood Experiences on Breastfeeding Initiation and Exclusivity: Findings from a National Population Health Survey. Breastfeeding Medicine, 2016, 11, 544-550.	0.8	9
262	Standardising definitions for the pre-eclampsia core outcome set: A consensus development study. Pregnancy Hypertension, 2020, 21, 208-217.	0.6	9
263	"Women and children lastâ€â€"effects of the covid-19 pandemic on reproductive, perinatal, and paediatric health. BMJ, The, 2020, 369, m2287.	3.0	9
264	The impact of preâ€eclampsia definitions on the identification of adverse outcome risk in hypertensive pregnancy – analyses from the CHIPS trial (Control of Hypertension in Pregnancy Study). BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1373-1382.	1.1	9
265	An International Benchmarking Collaboration: Measuring Outcomes for the Hypertensive Disorders of Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 794-800.	0.3	8
266	Our Patients Do Not Need Endocarditis Prophylaxis for Genitourinary Tract Procedures: Insights From the 2007 American Heart Association Guidelines. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 796-799.	0.3	8
267	Unexpected random urinary protein:creatinine ratio results–limitations of the pyrocatechol violet-dye method. BMC Pregnancy and Childbirth, 2013, 13, 152.	0.9	8
268	Women's views and postpartum follow-up in the CHIPS Trial (Control of Hypertension in Pregnancy) Tj ETQq0 0	0 rgBT /0	verlock 10 Tf
269	Strategies to reduce the global burden of direct maternal deaths. Obstetric Medicine, 2017, 10, 5-9.	0.5	8

270Creating biobanks in low and middle-income countries to improve knowledge â€" The PREPARE initiative.0.68270Pregnancy Hypertension, 2018, 13, 62-64.0.68

#	Article	IF	CITATIONS
271	Place-specific factors associated with adverse maternal and perinatal outcomes in Southern Mozambique: a retrospective cohort study. BMJ Open, 2019, 9, e024042.	0.8	8
272	Effect of COVID-19 on maternal and neonatal services. The Lancet Global Health, 2021, 9, e112.	2.9	8
273	External validation of prognostic models to predict stillbirth using International Prediction of Pregnancy Complications (<scp>IPPIC</scp>) Network database: individual participant data metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2022, 59, 209-219.	0.9	8
274	Community Health Worker Evaluation of Implementing an mHealth Application to Support Maternal Health Care in Rural India. Frontiers in Global Women S Health, 2021, 2, 645690.	1.1	8
275	Neutrophil apoptosis in preeclampsia, do steroids confound the relationship?. Journal of Obstetrics and Gynaecology Research, 2004, 30, 342-348.	0.6	7
276	mRNA induces RANTES production in trophoblast cells via TLR3 only when delivered intracellularly using lipid membrane encapsulation. Placenta, 2011, 32, 500-505.	0.7	7
277	Maternal circulating PIGF concentrations and placenta-related pregnancy complications: First results from the CoLab AngF Study. Pregnancy Hypertension, 2013, 3, 59.	0.6	7
278	Fetal, Infant and Maternal Outcomes among Women with Prolapsed Membranes Admitted before 29 Weeks Gestation. PLoS ONE, 2016, 11, e0168285.	1.1	7
279	A comparison of maternal and newborn health services costs in Sindh Pakistan. PLoS ONE, 2018, 13, e0208299.	1.1	7
280	Availability and use of magnesium sulphate at health care facilities in two selected districts of North Karnataka, India. Reproductive Health, 2018, 15, 91.	1.2	7
281	Covid-19: UK Obstetric Surveillance System (UKOSS) study in context. BMJ, The, 2020, 370, m2915.	3.0	7
282	The PRECISE (PREgnancy Care Integrating translational Science, Everywhere) database: open-access data collection in maternal and newborn health. Reproductive Health, 2020, 17, 50.	1.2	7
283	Maternal Risk Modeling in Critical Care—Development of a Multivariable Risk Prediction Model for Death and Prolonged Intensive Care*. Critical Care Medicine, 2020, 48, 663-672.	0.4	7
284	The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: A randomized placebo-controlled study. Pregnancy Hypertension, 2021, 23, 91-96.	0.6	7
285	The effect of factor V Leiden carriage on maternal and fetal health. Cmaj, 2002, 167, 48-54.	0.9	7
286	Anesthesia for the parturient with pseudoxanthoma elasticum. International Journal of Obstetric Anesthesia, 2003, 12, 45-47.	0.2	6
287	Activated protein C and the ovarian hyperstimulation syndrome: Possible therapeutic implications. Medical Hypotheses, 2006, 66, 929-933.	0.8	6
288	Calcium reduces risk of pre-eclampsia – Authors' reply. Lancet, The, 2010, 376, 1986-1987.	6.3	6

#	Article	IF	CITATIONS
289	Random urine albumin:creatinine ratio in high-risk pregnancy – ls it clinically useful?. Pregnancy Hypertension, 2013, 3, 112-114.	0.6	6
290	Measurement of sST2 is comparable to PIGF in the diagnosis of early-onset pre-eclampsia. Pregnancy Hypertension, 2013, 3, 115-117.	0.6	6
291	Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy and Childbirth, 2015, 15, 347.	0.9	6
292	Self-reported maternal morbidity: Results from the community level interventions for pre-eclampsia (CLIP) baseline survey in Sindh, Pakistan. Pregnancy Hypertension, 2019, 17, 113-120.	0.6	6
293	Placental growth factor for the prognosis of women with preeclampsia (fullPIERS model extension): context matters. BMC Pregnancy and Childbirth, 2020, 20, 668.	0.9	6
294	PRECISE pregnancy cohort: challenges and strategies in setting up a biorepository in sub-Saharan Africa. Reproductive Health, 2020, 17, 54.	1.2	6
295	Early prenatal use of a multivitamin diminishes the risk for inadequate vitamin D status in pregnant women: results from the Maternal-Infant Research on Environmental Chemicals (MIREC) cohort study. American Journal of Clinical Nutrition, 2021, 114, 1238-1250.	2.2	6
296	Nifedipine for Severe Hypertension in Pregnancy: Emotion or Evidence?. Journal of Obstetrics and Gynaecology Canada, 2005, 27, 260-262.	0.3	5
297	Indications for, Timing of, and Modes of Delivery in a National Cohort of Women Admitted With Antepartum Hemorrhage at 22+0 to 28+6 Weeks' Gestation. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 1043-1052.	0.3	5
298	External validation of a model for periconceptional prediction of recurrent early-onset preeclampsia. Hypertension in Pregnancy, 2014, 33, 265-276.	0.5	5
299	Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. Journal of Obstetrics and Gynaecology Canada, 2016, 38, 936-944.e3.	0.3	5
300	Determinants of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia. PLoS ONE, 2017, 12, e0189966.	1.1	5
301	Obstetric fistulae in southern Mozambique: incidence, obstetric characteristics and treatment. Reproductive Health, 2017, 14, 147.	1.2	5
302	Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial. Pregnancy Hypertension, 2018, 13, 121-126.	0.6	5
303	PREPARE: protocol for a stepped wedge trial to evaluate whether a risk stratification model can reduce preterm deliveries among women with suspected or confirmed preterm pre-eclampsia. BMC Pregnancy and Childbirth, 2019, 19, 343.	0.9	5
304	Policy review on the management of pre-eclampsia and eclampsia by community health workers in Mozambique. Human Resources for Health, 2019, 17, 15.	1.1	5
305	COVID-19 and preterm birth. The Lancet Global Health, 2021, 9, e117.	2.9	5
306	Management of Preeclampsia in Low- and Middle-Income Countries: Lessons to Date, and Questions Arising, from the PRE-EMPT and Related Initiatives. Maternal-Fetal Medicine, 2021, 3, 136-150.	0.4	5

#	Article	IF	CITATIONS
307	Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 227, 294.e1-294.e11.	0.7	5
308	What is SNOMED CT® and Why Should the ISSHP Care?. Hypertension in Pregnancy, 2009, 28, 119-121.	0.5	4
309	Current controversies in prenatal diagnosis 4: pregnancy complications due to placental vascular disease (preâ€eclampsia, FGR): are we ready for prevention?. Prenatal Diagnosis, 2013, 33, 17-20.	1.1	4
310	Early Administration of Low-Dose Aspirin for the Prevention of Severe and Mild Preeclampsia: A Systematic Review and Meta-Analysis. American Journal of Perinatology, 2014, 31, e3-e3.	0.6	4
311	Diagnostic, évaluation et prise en charge des troubles hypertensifs de la grossesse : Résumé directif. Journal of Obstetrics and Gynaecology Canada, 2016, 38, S426-S452.	0.3	4
312	CHIPS-Child: Testing the developmental programming hypothesis in the offspring of the CHIPS trial. Pregnancy Hypertension, 2018, 14, 15-22.	0.6	4
313	Prepregnancy and Early Pregnancy Calcium Supplementation Among Women at High Risk of Pre-eclampsia: A Multicentre, Double-blind, Randomised, Placebo-Controlled Trial. Obstetrical and Gynecological Survey, 2019, 74, 321-323.	0.2	4
314	Interactions between the Physical and Social Environments with Adverse Pregnancy Events Related to Placental Disorders—A Scoping Review. International Journal of Environmental Research and Public Health, 2020, 17, 5421.	1.2	4
315	The contribution of qualitative research within the PRECISE study in sub-Saharan Africa. Reproductive Health, 2020, 17, 58.	1.2	4
316	Authors' reply re: Maternity services in the UK during the coronavirus disease 2019 pandemic: a national survey of modifications to standard care. BJOC: an International Journal of Obstetrics and Gynaecology, 2021, 128, 937-938.	1.1	4
317	Implementation of the PIERS on the Move mHealth Application From the Perspective of Community Health Workers and Nurses in Rural Mozambique. Frontiers in Global Women S Health, 2021, 2, 659582.	1.1	4
318	Economic and cost-effectiveness analysis of the Community-Level Interventions for Pre-eclampsia (CLIP) trials in India, Pakistan and Mozambique. BMJ Global Health, 2021, 6, e004123.	2.0	4
319	Pregnancy Outcomes and Blood Pressure Visit-to-Visit Variability and Level in Three Less-Developed Countries. Hypertension, 2021, 77, 1714-1722.	1.3	4
320	Pregnancy cohorts and biobanking in sub-Saharan Africa: a systematic review. BMJ Global Health, 2020, 5, e003716.	2.0	4
321	Diagnosis and Monitoring of White Coat Hypertension in Pregnancy: an ISSHP Consensus Delphi Procedure. Hypertension, 2022, 79, 993-1005.	1.3	4
322	Halting the Canadian STRIDER randomised controlled trial of sildenafil for severe, early-onset fetal growth restriction: ethical, methodological, and pragmatic considerations. BMC Research Notes, 2022, 15, .	0.6	4
323	A Current Landscape of Provincial Perinatal Data Collection in Canada. Journal of Obstetrics and Gynaecology Canada, 2009, 31, 236-246.	0.3	3
324	PP088. Oral antihypertensive therapy for severe hypertension in pregnancy. Pregnancy Hypertension, 2012, 2, 288.	0.6	3

#	Article	IF	CITATIONS
325	Development and validation of prediction models for risk of adverse outcomes in women with early-onset pre-eclampsia: protocol of the prospective cohort PREP study. Diagnostic and Prognostic Research, 2017, 1, 6.	0.8	3
326	SOCIETAL PERSPECTIVE ON COST DRIVERS FOR HEALTH TECHNOLOGY ASSESSMENT IN SINDH, PAKISTAN. International Journal of Technology Assessment in Health Care, 2017, 33, 192-198.	0.2	3
327	"Now You Have Become Doctorsâ€i Lady Health Workers' Experiences Implementing an mHealth Application in Rural Pakistan. Frontiers in Global Women S Health, 2021, 2, 645705.	1.1	3
328	Population-level data on antenatal screening for proteinuria; India, Mozambique, Nigeria, Pakistan. Bulletin of the World Health Organization, 2020, 98, 661-670.	1.5	3
329	Prognostic Value of an Estimate-of-Risk Model in Critically Ill Obstetric Patients in Brazil. Obstetrics and Gynecology, 2022, 139, 83-90.	1.2	3
330	Anemia and adverse outcomes in pregnancy: subgroup analysis of the CLIP cluster-randomized trial in India. BMC Pregnancy and Childbirth, 2022, 22, 407.	0.9	3
331	Prediction of Adverse Maternal Outcomes in Preeclampsia: Development and Validation of the FullPIERS Model. Obstetrical and Gynecological Survey, 2011, 66, 267-268.	0.2	2
332	Preface. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 389-390.	1.4	2
333	Viagra for fetal growth restriction: STRIDER Consortium replies to letter by Symonds and Budge. BMJ: British Medical Journal, 2018, 363, k4872.	2.4	2
334	Ready for prime time–prediction of preterm preâ€eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 971.	1.1	2
335	Management of Hypertension in Pregnancy. Maternal-Fetal Medicine, 2021, 3, 124-135.	0.4	2
336	The ability and safety of community-based health workers to safely initiate lifesaving therapies for pre-eclampsia in Ogun State, Nigeria: An analysis of 260 community treatments with MgSO4 and/or methyldopa. Pregnancy Hypertension, 2021, 25, 179-184.	0.6	2
337	Feasibility of task-sharing with community health workers for the identification, emergency management and referral of women with pre-eclampsia, in Mozambique. Reproductive Health, 2021, 18, 145.	1.2	2
338	SARS-CoV-2 Infection in Pregnant Women and Their Newborns. Annals of Global Health, 2020, 86, 132.	0.8	2
339	Short-term outcomes of phosphodiesterase type 5 inhibitors for fetal growth restriction: a study protocol for a systematic review with individual participant data meta-analysis, aggregate meta-analysis, and trial sequential analysis. Systematic Reviews, 2021, 10, 305.	2.5	2
340	Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics and Gynecology, 2003, 101, 618.	1.2	1
341	PRE-ECLAMPSIA AS A MARKER OF CARDIOVASCULAR DISEASE. Fetal and Maternal Medicine Review, 2008, 19, 271-292.	0.3	1
342	Review: multiple doses of antenatal corticosteroids prevent preterm neonatal respiratory disease more than a single dose. Evidence-Based Medicine, 2008, 13, 81-81.	0.6	1

#	Article	IF	CITATIONS
343	Prediction of pre-eclampsia complications – Authors' reply. Lancet, The, 2011, 377, 1314.	6.3	1
344	Recours au sulfate de magnésium à des fins de neuroprotection fœtale. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 530-545.	0.3	1
345	Clinical risk prediction of pre-eclampsia. BMJ: British Medical Journal, 2011, 342, d1863-d1863.	2.4	1
346	The PIERS Experience: Research or Quality Improvement?. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 379-381.	0.3	1
347	PP025. Urinary dipstick proteinuria testing – Does automated strip analysis offer an advantage over visual testing?. Pregnancy Hypertension, 2012, 2, 255-256.	0.6	1
348	PP174. Timely prediction of maternal complications in pre-eclampsia analysis of the fullPIERS model. Pregnancy Hypertension, 2012, 2, 334-335.	0.6	1
349	"34 Weeks―of Gestation—Lost in Translation. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 480-481.	0.3	1
350	In Response. Journal of Obstetrics and Gynaecology Canada, 2015, 37, 775-776.	0.3	1
351	Less-Tight Versus Tight Control of Hypertension in Pregnancy. Obstetrical and Gynecological Survey, 2015, 70, 307-308.	0.2	1
352	No 376 - Recours au sulfate de magnésium aux fins de neuroprotection fœtale. Journal of Obstetrics and Gynaecology Canada, 2019, 41, 523-542.	0.3	1
353	Investigating placental disorders of pregnancy in sub-Saharan Africa: addressing the gap in a neglected area of research. Reproductive Health, 2020, 17, 53.	1.2	1
354	Harnessing the PRECISE network as a platform to strengthen global capacity for maternal and child health research in sub-Saharan Africa. Reproductive Health, 2020, 17, 52.	1.2	1
355	OS032. Pharmacotherapy for pre-eclampsia in low and middle income countries: An analysis of essential medicines lists (EMLS). Pregnancy Hypertension, 2012, 2, 193-4.	0.6	1
356	A Note on the Publication ofThe Magnitude of Hemoconcentration with Eclampsia. Hypertension in Pregnancy, 2009, 28, 123-123.	0.5	0
357	PP023. Unexpected random urinary protein: creatinine ratio results – Insightsfrom clinician-laboratory medicine collaboration. Pregnancy Hypertension, 2012, 2, 253.	0.6	0
358	PP024. Random urine albumin: Creatinine ratio in high-risk pregnancy – Is it clinically useful?. Pregnancy Hypertension, 2012, 2, 253-255.	0.6	0
359	PP164. Magnesium sulphate for prevention and treatment of eclampsia in low and middle income countries: Systematic review of tested regimens. Pregnancy Hypertension, 2012, 2, 328.	0.6	0
360	Reversed umbilical arterial end diastolic flow, sildenafil treatment and early stillbirths. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 510-510.	1.1	0

#	Article	IF	CITATIONS
361	Maternal and Perinatal Outcomes of Pregnancies Delivered at 23 Weeks' Gestation. Obstetrical and Gynecological Survey, 2015, 70, 432-434.	0.2	0
362	Are long-term health risks of pre-eclampsia and intrauterine growth restriction really the same?. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 1824-1824.	1.1	0
363	How accurate are modelled birth and pregnancy estimates? Comparison of four models using high resolution maternal health census data in southern Mozambique. BMJ Global Health, 2019, 4, e000894.	2.0	0
364	Oral Antihypertensive Regimens (Nifedipine Retard, Labetalol, and Methyldopa) for Management of Severe Hypertension in Pregnancy: An Open-Label, Randomized Controlled Trial. Obstetrical and Gynecological Survey, 2020, 75, 81-83.	0.2	0
365	Management of Severe Preeclampsia and Eclampsia. , 2021, , 26-34.		0
366	Preeclampsia: Blood Pressure, Weight Gain, and Edema. , 2006, , 394-407.		0
367	How Gender Influenced the Experience of Using a mHealth Intervention in Rural Mozambique: Secondary Qualitative Analysis of Community Health Worker Survey Data. Frontiers in Global Women S Health, 2022, 3, 661000.	1.1	0
368	Re: Reducing health inequality in Black, Asian and other minority ethnic pregnant women: Impact of firstâ€ŧrimester combined screening for placental dysfunction on perinatal mortality. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, , .	1.1	0
369	Directive clinique no 426 : Troubles hypertensifs de la grossesse : Diagnostic, prédiction, prévention etÂprise en charge. Journal of Obstetrics and Gynaecology Canada, 2022, 44, 572-597.e1.	0.3	0
370	Identifying potentially eligible subjects for research: paper-based logs versus the hospital administrative database. Chronic Diseases and Injuries in Canada, 2011, 32, 43-46.	1.4	0